Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices

This article was originally published in The Pink Sheet Daily

Executive Summary

The federal government will have to take the lead on investigating and potentially punishing past overcharging for drugs as a result of the March 29 ruling.

You may also be interested in...



340B Drug Discount Fight Moves To States As PhRMA Opposes Louisiana Law

PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.

Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment

Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.

Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities

U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel